Literature DB >> 32471009

Absence of images of skin of colour in publications of COVID-19 skin manifestations.

J C Lester1, J L Jia2, L Zhang3, G A Okoye4, E Linos3.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32471009      PMCID: PMC7301030          DOI: 10.1111/bjd.19258

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   11.113


× No keyword cloud information.
Dear Editor, There are now over 1 million confirmed cases of COVID‐19 globally, with more than 270 000 recorded deaths to date.1 COVID‐19 has been shown to impact people of colour disproportionately, both in the UK and in the USA, where black people make up 13·4% of the population but 30% of cases of COVID‐19.2, 3 Mounting evidence shows that COVID‐19 impacts several organ systems, including the skin.4 Knowledge of cutaneous manifestations of COVID‐19 and the ability to identify them in patients of all skin types is important for dermatologists and other healthcare providers who may be evaluating patients who are otherwise asymptomatic. In order to provide optimal care to all patients, it is therefore important that we are able to identify cutaneous manifestations of COVID‐19 in patients with darker skin. We completed a systematic literature review, using the PRISMA guidelines, of all articles describing cases of cutaneous manifestations associated with COVID‐19. We included English‐language articles published between 31 December 2019 and 3 May 2020. We extracted patient case numbers, race and ethnicity descriptors when available, photographs, and descriptions of cutaneous manifestations. In order to assess background skin colour, a board‐certified dermatologist with expertise in diagnosing and treating patients with skin of colour (Fitzpatrick type IV–VI) evaluated each of the images and categorized them based on Fitzpatrick type I–VI. We collated these images, ordered by skin type (Figure 1a). We then manually selected a pixel of background skin, unaffected by the rash, from each image. In order to adjust for lighting conditions, we then standardized the lightness portion of the hue–saturation–lightness scale of this pixel within each coded Fitzpatrick category, thus approximating true skin colour (Figure 1b).
Figure 1

(a) Images of cutaneous manifestations associated with COVID‐19. (b) Approximation of the skin colour of the patients in (a). All images are reproduced with permission of the respective copyright owners.

(a) Images of cutaneous manifestations associated with COVID‐19. (b) Approximation of the skin colour of the patients in (a). All images are reproduced with permission of the respective copyright owners. Forty‐six articles met our inclusion criteria. Of those, 36 articles included clinical photos of COVID‐19‐related skin lesions for a total of 130 images. We obtained permission to use 116 of these images in this publication, and they are shown in Figure 1. In total, 92% (120 of 130) showed skin types I–III, 6% (seven of 130) showed patients with type IV skin and 2% (three of 130) could not be classified because they depicted only acral skin. There were no clinical images representing Fitzpatrick type V or VI skin. Photographed eruptions among skin of Fitzpatrick phototypes I–III included chilblain‐like, urticarial, maculopapular and vesicular lesions. The images among patients with Fitzpatrick phototype IV included chilblain‐like lesions and necrotic purpura only. In the six articles with race and ethnicity information, 91% of the patients mentioned were reported to be white and 9% were Hispanic. Our analysis demonstrates that articles describing the cutaneous manifestations of COVID‐19 almost exclusively show clinical images from patients with lighter skin. Based on our analysis, there are no published photos of the cutaneous manifestations in dark skin (Fitzpatrick type V or VI). This is a problem because skin disease often presents differently in skin of colour.5 We have previously reported imbalances in representation of Fitzpatrick skin types in dermatology textbooks7 and in dermatology journals.6, 7 This can lead to cognitive biases that can also impact differential diagnoses and physician–patient relationships.6 Forty‐seven per cent of dermatologists report insufficient exposure to patients with darker skin during their training, and this directly impacts the quality of patient care.6, 8 One way to mitigate this deficiency is to increase the availability of images in teaching materials and dermatological journals.8 We will not be able to attain this goal without an explicit commitment to documenting, photographing and publishing the manifestations of this disease in a wide variety of skin tones. Our study is limited by the subjective assessment of skin type from a photograph. Lighting conditions including overexposure may have made dark skin look lighter, and this may have led to some misclassification across one or two skin types. However, it is unlikely that lighting issues alone would result in skin types V or VI appearing as skin type I–III. The paucity of images of skin manifestations of COVID‐19 in patients with darker skin is a problem, because it may make identification of COVID‐19 presenting with cutaneous manifestations more difficult for both dermatologists and the public. Given the racial disparities in COVID‐19 infections and associated deaths, it is important that all manifestations of this disease contain broad representation of people of different races and ethnicities, as any clue, if recognized, could contribute to early diagnosis and potentially better health outcomes. Dermatologists should prioritize identification of cutaneous manifestations of COVID‐19 in patients with darker skin by photographing and disseminating these findings. Journals should prioritize publication of manuscripts depicting the cutaneous manifestations of COVID‐19 in darker skin because exclusion of these patients from the literature may further exacerbate existing health disparities.
  4 in total

1.  Under-representation of skin of colour in dermatology images: not just an educational issue.

Authors:  J C Lester; S C Taylor; M-M Chren
Journal:  Br J Dermatol       Date:  2019-06       Impact factor: 9.302

Review 2.  Dermatologic health disparities.

Authors:  Kesha J Buster; Erica I Stevens; Craig A Elmets
Journal:  Dermatol Clin       Date:  2012-01       Impact factor: 3.478

3.  Dermatologic conditions in skin of color: part I. Special considerations for common skin disorders.

Authors:  Roopal V Kundu; Stavonnie Patterson
Journal:  Am Fam Physician       Date:  2013-06-15       Impact factor: 3.292

4.  Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases.

Authors:  C Galván Casas; A Català; G Carretero Hernández; P Rodríguez-Jiménez; D Fernández-Nieto; A Rodríguez-Villa Lario; I Navarro Fernández; R Ruiz-Villaverde; D Falkenhain-López; M Llamas Velasco; J García-Gavín; O Baniandrés; C González-Cruz; V Morillas-Lahuerta; X Cubiró; I Figueras Nart; G Selda-Enriquez; J Romaní; X Fustà-Novell; A Melian-Olivera; M Roncero Riesco; P Burgos-Blasco; J Sola Ortigosa; M Feito Rodriguez; I García-Doval
Journal:  Br J Dermatol       Date:  2020-06-10       Impact factor: 11.113

  4 in total
  19 in total

1.  Under-representation of people of African ancestry in publications on the cutaneous manifestations of COVID-19: coincidence or physiology?

Authors:  C Cassius; L Frumholtz; A de Masson; O Dadzie; A Petit
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-04-29       Impact factor: 9.228

2.  Rarity of cutaneous findings among asymptomatic to mildly symptomatic patients with COVID-19 admitted to a COVID care facility in Delhi, India: an observational study.

Authors:  A Khurana; A Mittal; R Jain; A Mishra; S R Mathachan
Journal:  Br J Dermatol       Date:  2021-06-05       Impact factor: 11.113

3.  The spectrum of COVID-19-associated dermatologic manifestations: An international registry of 716 patients from 31 countries.

Authors:  Esther E Freeman; Devon E McMahon; Jules B Lipoff; Misha Rosenbach; Carrie Kovarik; Seemal R Desai; Joanna Harp; Junko Takeshita; Lars E French; Henry W Lim; Bruce H Thiers; George J Hruza; Lindy P Fox
Journal:  J Am Acad Dermatol       Date:  2020-07-02       Impact factor: 11.527

4.  Is there an under-representation of skin of colour images during the COVID-19 outbreak?

Authors:  Nicolas Kluger; Mahtab Samimi
Journal:  Med Hypotheses       Date:  2020-09-13       Impact factor: 1.538

5.  Pityriasis Rosea in Otherwise Asymptomatic Confirmed COVID-19 Positive Patients: A Report of Two Cases.

Authors:  Maija Johansen; Sarah S Chisolm; Laura Delong Aspey; Meera Brahmbhatt
Journal:  JAAD Case Rep       Date:  2020-11-07

6.  Paucity of COVID-19 dermatology literature from low- and middle-income countries.

Authors:  R S Pendse; B L Schwartz; J L Jia; E E Bailey
Journal:  Br J Dermatol       Date:  2020-09-29       Impact factor: 11.113

7.  Prurigo pigmentosa and new-onset type 1 diabetes in a black female patient testing positive for SARS-CoV-2 IgG.

Authors:  K M Derrick; D R Mazori; E R Heilman; S A Glick
Journal:  Br J Dermatol       Date:  2020-10-25       Impact factor: 11.113

8.  Immune checkpoint inhibition in the era of COVID-19.

Authors:  J Kurzhals; P Terheyden; E A Langan
Journal:  Clin Exp Dermatol       Date:  2020-09-12       Impact factor: 4.481

9.  Erythematous-edematous type of chilblain-like lesions and COVID-19: An Indian perspective.

Authors:  Anupam Das; Vinay Singh
Journal:  Dermatol Ther       Date:  2020-07-29       Impact factor: 3.858

10.  Recognizable vascular skin manifestations of SARS-CoV-2 (COVID-19) infection are uncommon in patients with darker skin phototypes.

Authors:  R Pangti; S Gupta; N Nischal; A Trikha
Journal:  Clin Exp Dermatol       Date:  2020-09-17       Impact factor: 4.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.